Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).

@article{Banno2012ProgestinTF,
  title={Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).},
  author={Kouji Banno and Iori Kisu and Megumi Yanokura and Kosuke Tsuji and Kenta Masuda and Arisa Ueki and Yusuke Kobayashi and Wataru Yamagami and Hiroyuki Nomura and Nobuyuki Susumu and Daisuke Aoki},
  journal={International journal of oncology},
  year={2012},
  volume={40 6},
  pages={
          1755-62
        }
}
Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of… 
View on PubMed
spandidos-publications.com
38 Citations
Highly Influential Citations
2
Background Citations
15
Methods Citations
1

Figures and Tables from this paper

38 Citations

Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?
TLDR
The pathogenesis of gynecological malignancies from the hormonal landscape and the use of hormonal therapies toward clinical applications are discussed and the current knowledge gaps are identified.
Hormone therapy for younger patients with endometrial cancer.
New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)
TLDR
The background and early clinical evidence for metformin, microRNAs involved in the molecular mechanisms of oncogenesis and progression, and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis are reviewed.
Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.
TLDR
Fertility-sparing progestin therapy is highly effective in selected young women with primary and recurrent endometrial cancer and prophylactic hysterectomy is the best option for patients who have completed family planning.
AS DIENOGEST EFFECTIVELY SUPPRESSES ENDOMETRIOSIS, COULD IT ALSO REDUCE ENDOMETRIOSIS- ASSOCIATED OVARIAN CANCERS? A FURTHER MOTIVATION FOR LONG-TERM MEDICAL TREATMENT
TLDR
DNG has not only progestin effects, but it also suppresses endometriotic tissue growth, angiogenesis and inflammation and promotes apoptosis, which are mechanisms that could also reduce ovarian cancer growth.
A progestin isn’t a progestin: dienogest for endometriosis as a blueprint for future research – Review as a contribution for discussion -
TLDR
In light of the emerging multitude of pathomechanisms in endometriosis, a monotherapy may not be possible, and then the search for broad spectrum compounds or combination therapies with dual or multiple mode of action in a clinically relevant dose range might be considered.
Hormonal therapy in uterine sarcomas
TLDR
All the existing studies related to the hormonal therapy in USs are reviewed in order to provide reference for clinical management in specific settings and establish the optimal hormonal therapy regimen of USs.
Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report
TLDR
The patient was a 44-year-old woman with advanced adenosarcoma arising from the endometriosis in the rectovaginal space and infiltrating the left pelvic wall, left ureter, rectum and vagina, and the tumor remained stable up to 21 months.
The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia
TLDR
DIE is an effective and convenient method for thinning the endometrium and was similar between the groups, although there was no statistically significant difference between groups.
New Insights into Hormonal Therapies in Uterine Sarcomas
TLDR
The scope of the present review is to report the existing evidence and future perspectives on hormonal therapy in uterine sarcomas, with a special focus on aromatase inhibitors, progestins and gonadotropin-releasing hormone analogues, in order to clarify their potential role in daily clinical practice.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Endometrial cancer: reviving progesterone therapy in the molecular age.
TLDR
One current approach to restore expression of PR at the epigenetic level in endometrial cancer is described, and it is believed this strategy to re-establish PR expression will result in resensitization ofendometrial tumors to progestin therapy.
Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis
TLDR
Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors, and is expected to be an effective treatment for endometriosis.
The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro.
TLDR
Data imply that dienogest exerts direct effect in suppressing growth of endometriotic implants, and directly acts on endometrial tissue in progestogenic response, such as decidualization, increased prolactin production and growth retardation.
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
  • K. UshijimaH. Yahata T. Kamura
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The efficacy of fertility-sparing treatment with a high-dose of MPA for EC and AH was proven by this prospective trial, however, close follow-up is required because of the substantial rate of recurrence.
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
TLDR
Anastrozole has minimal activity in an unselected population of patients with recurrent endometrial cancer and the toxicity profile was mild.
Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials.
Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
Management of Endometriosis With Oral Medroxyprogesterone Acetate
TLDR
The findings indicate that oral MPA is a useful therapeutic agent in the management of minimal to moderate endometriosis, particularly when it is associated with infertility.
Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells.
Intrauterine progesterone treatment of early endometrial cancer.
TLDR
Intrauterine progesterone appears to eradicate some cases of presumed stage IA, grade 1 endometrioid cancer in women at high risk for perioperative morbidity.
...
...